Skip to main content
padlock icon - secure page this page is secure

Buprenorphine and Buprenorphine/Naloxone Diversion, Misuse, and Illicit Use: An International Review

Buy Article:

$68.00 + tax (Refund Policy)

The diversion, misuse, and non-medically supervised use of buprenorphine and buprenorphine/naloxone by opioid users are reviewed. Buprenorphine and buprenorphine/naloxone are used globally as opioid analgesics and in the treatment of opioid dependency. Diversion of buprenorphine and buprenorphine/naloxone represents a complex medical and social issue, and has been widely documented in various geographical regions throughout the world.

We first discuss the clinical properties of buprenorphine and its abuse potential. Second, we discuss its diversion and illicit use on an international level, as well as motivations for those activities. Third, we examine the medical risks and benefits of buprenorphine's non-medically supervised use and misuse. These risks and benefits include the effect of buprenorphine's use on HIV risk and the risk of its concomitant use with other medications and drugs of abuse. Finally, we discuss the implications of diversion, misuse, and non-medically supervised use (including potential measures to address issues of diversion); and potential areas for further research.



No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: Buprenorphine; Suboxone; Subutex; buprenorphine/naloxone; diversion; injection drug use; opiate abuse; opiate dependence; opioid abuse; opioid dependence; self treatment

Document Type: Research Article

Publication date: March 1, 2011

More about this publication?
  • Current Drug Abuse Reviews aims to publish the highest quality reviews, meta-analyses and drug clinical trial studies on all latest advances on alcohol and drug abuse and addiction.

    Book reviews are also published. The Journal will further comprise an agenda listing relevant meetings and conferences that will take place in near future, and advertisement.

  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more